Chlorprothixene
Taractan (chlorprothixene) is a small molecule pharmaceutical. Chlorprothixene was first approved as Taractan on 1982-01-01. It is used to treat paranoid schizophrenia and psychotic disorders in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
---|---|
mental disorders | D001523 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
1 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Diabetes insipidus | D003919 | E23.2 | — | — | — | — | 1 | 1 | |
Neurogenic diabetes insipidus | D020790 | HP_0000863 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | CHLORPROTHIXENE |
INN | chlorprothixene |
Description | Chlorprothixene is a member of thioxanthenes, a tertiary amino compound and an organochlorine compound. It has a role as a non-narcotic analgesic, an antiemetic, a sedative, a cholinergic antagonist, a dopaminergic antagonist and a first generation antipsychotic. It is a conjugate base of a chlorprothixene(1+). |
Classification | Small molecule |
Drug class | Typical antipsychotic |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CN(C)CC/C=C1/c2ccccc2Sc2ccc(Cl)cc21 |
Identifiers
PDB | — |
CAS-ID | 113-59-7 |
RxCUI | 2406 |
ChEMBL ID | CHEMBL908 |
ChEBI ID | 50931 |
PubChem CID | 667466 |
DrugBank | DB01239 |
UNII ID | 9S7OD60EWP (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 977 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
118 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more